Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ixabepilone

FDA-approved product (injectable, intravenous), marketed as Ixempra Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ixabepilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cytotoxic antibiotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ixabepilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ixabepilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of the Alternative Administration of Ixabepilone and Vinflunine

    NCT00362830 · start 2006-08

    Registered record
    Registry ID
    NCT00362830
    Conditions
    Cancer
    Interventions
    vinflunine + ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    Interventionvinflunine + ixabepilone
    PhasePhase 1
    Registry statusCompleted

  • Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

    NCT00207090 · start 2005-09

    Registered record
    Registry ID
    NCT00207090
    Conditions
    Advanced Solid Tumors; Neoplasms
    Interventions
    ixabepilone; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-11
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Neoplasms
    Interventionixabepilone; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer

    NCT00095979 · start 2005-05

    Registered record
    Registry ID
    NCT00095979
    Conditions
    Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Stage IV Endometrial Carcinoma
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-05
    Completion
    2009-07
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Stage IV Endometrial Carcinoma
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

    NCT00077376 · start 2005-03

    Registered record
    Registry ID
    NCT00077376
    Conditions
    HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventions
    trastuzumab; ixabepilone; carboplatin; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2011-03
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventiontrastuzumab; ixabepilone; carboplatin; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone in Treating Patients With Metastatic Prostate Cancer

    NCT00087139 · start 2004-09

    Registered record
    Registry ID
    NCT00087139
    Conditions
    Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2011-02
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

    NCT01018966 · start 2004-04

    Registered record
    Registry ID
    NCT01018966
    Conditions
    Solid Tumors
    Interventions
    Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-04
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionIxabepilone
    PhasePhase 1
    Registry statusCompleted

  • Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

    NCT00080262 · start 2004-02

    Registered record
    Registry ID
    NCT00080262
    Conditions
    Breast Cancer; Metastases
    Interventions
    Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2006-12
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Metastases
    InterventionIxabepilone
    PhasePhase 2
    Registry statusCompleted

  • S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

    NCT00049400 · start 2003-10

    Registered record
    Registry ID
    NCT00049400
    Conditions
    Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    BMS-247550
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10
    Completion
    2007-12
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    InterventionBMS-247550
    PhasePhase 1
    Registry statusCompleted

  • Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors

    NCT00096317 · start 2003-03

    Registered record
    Registry ID
    NCT00096317
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    ixabepilone; ketoconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-03
    Completion
    2005-12-05
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionixabepilone; ketoconazole
    PhasePhase 1
    Registry statusCompleted

  • Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

    NCT00058019 · start 2003-02

    Registered record
    Registry ID
    NCT00058019
    Conditions
    Anaplastic Large Cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-02
    Completion
    2010-08
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma +2 more
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

    NCT00052572 · start 2002-10

    Registered record
    Registry ID
    NCT00052572
    Conditions
    Leukemia; Lymphoma
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10
    Completion
    2007-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

    NCT00049244 · start 2002-09

    Registered record
    Registry ID
    NCT00049244
    Conditions
    Breast Cancer
    Interventions
    capecitabine; ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2002-09
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioncapecitabine; ixabepilone
    PhasePhase 1
    Registry statusUnknown

  • Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer

    NCT00045097 · start 2002-05

    Registered record
    Registry ID
    NCT00045097
    Conditions
    Breast Cancer
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-05
    Completion
    2007-07
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

    NCT00057850 · start 2002-01

    Registered record
    Registry ID
    NCT00057850
    Conditions
    Head and Neck Cancer
    Interventions
    cisplatin; ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    Not recorded
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventioncisplatin; ixabepilone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer

    NCT00022477 · start 2001-09

    Registered record
    Registry ID
    NCT00022477
    Conditions
    Colorectal Cancer
    Interventions
    BMS-247550
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-09
    Completion
    2004-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionBMS-247550
    PhasePhase 2
    Registry statusCompleted